Drägerwerk AG & Co. KGaA

XTRA:DRW3 Stock Report

Market Cap: €864.8m

Drägerwerk KGaA Valuation

Is DRW3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DRW3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DRW3 (€47.75) is trading below our estimate of fair value (€115.66)

Significantly Below Fair Value: DRW3 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for DRW3?

Other financial metrics that can be useful for relative valuation.

DRW3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA4.9x
PEG Ratio15.1x

Price to Earnings Ratio vs Peers

How does DRW3's PE Ratio compare to its peers?

The above table shows the PE ratio for DRW3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.5x
EUZ Eckert & Ziegler
22.8x4.0%€859.7m
SBS Stratec
35.6x19.8%€518.5m
PUS PULSION Medical Systems
26.2xn/a€131.9m
AFX Carl Zeiss Meditec
29.6x17.9%€6.0b
DRW3 Drägerwerk KGaA
7.7x0.5%€864.8m

Price-To-Earnings vs Peers: DRW3 is good value based on its Price-To-Earnings Ratio (7.7x) compared to the peer average (28.5x).


Price to Earnings Ratio vs Industry

How does DRW3's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: DRW3 is good value based on its Price-To-Earnings Ratio (7.7x) compared to the European Medical Equipment industry average (29.6x).


Price to Earnings Ratio vs Fair Ratio

What is DRW3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DRW3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.7x
Fair PE Ratio15.2x

Price-To-Earnings vs Fair Ratio: DRW3 is good value based on its Price-To-Earnings Ratio (7.7x) compared to the estimated Fair Price-To-Earnings Ratio (15.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DRW3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€48.70
€58.00
+19.1%
18.1%€70.00€42.00n/a4
Oct ’25€47.25
€58.00
+22.8%
18.1%€70.00€42.00n/a4
Sep ’25€45.90
€58.00
+26.4%
18.1%€70.00€42.00n/a4
Aug ’25€47.60
€58.00
+21.8%
18.1%€70.00€42.00n/a4
Jul ’25€49.95
€58.00
+16.1%
18.1%€70.00€42.00n/a4
Jun ’25€50.30
€57.50
+14.3%
17.8%€70.00€42.00n/a4
May ’25€49.70
€57.50
+15.7%
17.8%€70.00€42.00n/a4
Apr ’25€50.90
€56.25
+10.5%
15.7%€65.00€42.00n/a4
Mar ’25€47.10
€56.25
+19.4%
15.7%€65.00€42.00n/a4
Feb ’25€47.25
€56.25
+19.0%
15.7%€65.00€42.00n/a4
Jan ’25€51.80
€54.00
+4.2%
18.3%€65.00€38.00n/a4
Dec ’24€52.00
€54.00
+3.8%
18.3%€65.00€38.00n/a4
Nov ’24€47.70
€50.28
+5.4%
20.0%€65.00€38.00n/a4
Oct ’24€42.45
€50.28
+18.4%
20.0%€65.00€38.00€47.254
Sep ’24€45.00
€50.28
+11.7%
20.0%€65.00€38.00€45.904
Aug ’24€45.00
€49.78
+10.6%
21.4%€65.00€36.00€47.604
Jul ’24€43.55
€47.53
+9.1%
22.5%€65.00€36.00€49.954
Jun ’24€42.35
€55.62
+31.3%
33.8%€88.00€36.00€50.305
May ’24€51.00
€55.62
+9.1%
33.8%€88.00€36.00€49.705
Apr ’24€42.35
€53.28
+25.8%
38.2%€88.00€36.00€50.904
Mar ’24€41.30
€52.81
+27.9%
39.0%€88.00€36.00€47.104
Feb ’24€42.00
€52.81
+25.7%
39.0%€88.00€36.00€47.254
Jan ’24€41.75
€55.08
+31.9%
34.6%€88.00€42.00€51.804
Dec ’23€43.65
€55.08
+26.2%
34.6%€88.00€42.00€52.004
Nov ’23€41.85
€55.08
+31.6%
34.6%€88.00€42.00€47.704
Oct ’23€42.85
€59.19
+38.1%
28.1%€88.00€48.75€42.454

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies